ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Administrative Data"

  • Abstract Number: 0347 • ACR Convergence 2022

    Real-World Effectiveness of Belimumab in Patients with SLE in the United States

    Christopher Bell1, Bernie Rubin2, Karen Worley3, Guillaume Germain4, François Laliberté4, Sean D. MacKnight4, Ana Urosevic4 and Mei Sheng Duh5, 1GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, 2GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, 3GlaxoSmithKline, US Value, Evidence and Outcomes, Cincinnati, OH, 4Groupe d’analyse, Montréal, QC, Canada, 5Analysis Group Inc, Boston, MA

    Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…
  • Abstract Number: 1199 • ACR Convergence 2022

    Validation of New Medication User Definitions in Single-Specialty EHR Data

    Jeffrey Curtis1, Yujie Su2, Michael george3, Cassie Clinton2, Patrick Stewart4, Tim Buekelman5 and Fenglong Xie2, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3UPENN, Philadelphia, PA, 4Bendcare, Boca Raton, FL, 5FASTER, Hoover, AL

    Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…
  • Abstract Number: 0354 • ACR Convergence 2022

    Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States

    Sandra Sze-jung Wu1, Allison Perry2, Helen Varker3, Rich Bizier3, Liisa Palmer3 and Gary Bryant4, 1AstraZeneca, Hockessin, DE, 2IBM Watson Health, New York, NY, 3Merative, Cambridge, MA, 4AstraZeneca, New Castle, DE

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease associated with periods of flares. Identifying patients at risk of severe disease and associated resource…
  • Abstract Number: 1378 • ACR Convergence 2022

    Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort

    Ha-Seul Jeoung1, Kuan Liu1, Roberta Berard2, Wes Fidler3, Janet Pope4, Johannes Roth5, Carter Thorne6, Earl Silverman7 and Deborah Levy8, 1University of Toronto, Toronto, ON, Canada, 2London Health Sciences Centre, London, ON, Canada, 3St. Joseph's Hospital, Thunder Bay, ON, Canada, 4University of Western Ontario, London, ON, Canada, 5University of Ottawa, Ottawa, Canada, 6Southlake Regional Health Centre, Newmarket, ON, Canada, 7The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 8Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill…
  • Abstract Number: 0550 • ACR Convergence 2022

    Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research

    Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…
  • Abstract Number: 1488 • ACR Convergence 2022

    Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study

    David Singer1, Philippe Thompson-Leduc2, Siyu Ma3, Deepshekhar Gupta4, Wendy Cheng5, Selvam Sendhil6, Manasvi Sundar6, Ella Hagopian5, Mei Sheng Duh7 and Sara Poston1, 1GSK, Philadelphia, PA, 2Analysis Group, Inc., Montréal, QC, Canada, 3GSK/Tufts Medical Center, Boston, MA, 4Analysis Group, Inc., Menlo Park, CA, 5Analysis Group, Inc., Boston, MA, 6Analysis Group, Inc., Los Angeles, CA, 7Analysis Group Inc, Boston, MA

    Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…
  • Abstract Number: 0707 • ACR Convergence 2022

    Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis

    Rachel W. Galvao1, Jeffrey Curtis2, Leslie Harrold3, Qufei Wu4, Fenglong Xie5 and Michael George4, 1Yale University, New Haven, CT, 2University of Alabama at Birmingham, Hoover, AL, 3CorEvitas, LLC, Waltham, MA, 4University of Pennsylvania, Philadelphia, PA, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Glucocorticoids (GCs) are used commonly to treat patients with rheumatoid arthritis (RA) and other inflammatory conditions. As clinical trials are often underpowered to assess…
  • Abstract Number: 1591 • ACR Convergence 2022

    Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population

    Sandra Sze-jung Wu1, Gelareh Atefi2, Meghan Moynihan3, Kristin Evans3, Liisa Palmer3, Michael Pollack2, Christine Dube4 and Cassandra Calabrese5, 1AstraZeneca, Hockessin, DE, 2AstraZeneca, Wilmington, DE, 3Merative, Cambridge, MA, 4AstraZeneca, Torrington, CT, 5Cleveland Clinic Foundation, Cleveland Heights, OH

    Background/Purpose: To assess the prevalence of severe COVID-19 (COVID) overall and following vaccination among patients with systemic lupus erythematosus (SLE) and the general population, and…
  • Abstract Number: L11 • ACR Convergence 2021

    Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study

    ELVIRA D'ANDREA1, Rishi Desai2, Mengdong He3, Robert Glynn4, Hemin Lee2, Michael Weinblatt2, Daniel Solomon5 and Seoyoung Kim2, 1Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Brigham & Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
  • Abstract Number: L16 • ACR Convergence 2021

    Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository

    Jasvinder Singh1, Namrata Singh2, Alfred Anzalone3, Amy Olex4, Jing Sun5, Vithal Madhira6 and Rena Patel7, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Washington, Bellevue, WA, 3University of Nebraska, Omaha, NE, 4Virginia Commonwealth University, Richmond, VA, 5Johns Hopkins University, Baltimore, MD, 6Palila Software, Reno, NV, 7Unviersity of Washington, Seattle, WA

    Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
  • Abstract Number: L06 • ACR Convergence 2021

    Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach

    Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…
  • Abstract Number: 0493 • ACR Convergence 2021

    Hospitalization for SLE Flare Has Reduced over Two Decades in the United States: A Longitudinal Population-based Study

    Ehizogie Edigin1, Precious Eseaton2, Chinenye Osuorji3, Nneka Chukwu4, Oluyemisi Amoda5, Kolade Olabode6 and Augustine Manadan7, 1Internal Medicine, John H Stroger Jr. Hospital of Cook County, Chicago, IL, 2University of Benin, Benin, Nigeria, 3Internal Medicine, Burrell College of Osteopathic Medicine, Las Cruces, NM, 4Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, 5Internal Medicine, Brookdale University hospital and medical center, New York, NY, 6College of Public Health, Kent State University, Kent, OH, 7Rush University Medical Center, Chicago, IL

    Background/Purpose: Longitudinal data are limited on SLE flare hospitalizations. This study aims to study longitudinal trends of SLE flare hospitalizations in the last 2 decades…
  • Abstract Number: 0495 • ACR Convergence 2021

    Racial/Ethnic Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study

    Ali Duarte-Garcia1, Herbert Heien1, Nilay Shah1 and Cynthia Crowson2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased burden of multimorbidity. Racial/ethnic disparities have also been associated with an increased burden of multimorbidity.…
  • Abstract Number: 0561 • ACR Convergence 2021

    Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports

    Brent Luedders1, Brendan Cope2, Matt Devries2, W. Scott Campbell2, James Campbell2, Ted Mikuls3, Jeffrey Curtis4, Daniel Hershberger3 and Bryant England3, 1University of Nebraska Medical Center, Omaha, NE, United Kingdom, 2University of Nebraska Medical Center, Omaha, 3University of Nebraska Medical Center, Omaha, NE, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Interstitial lung disease (ILD) is an extraarticular manifestation of RA that leads to increased morbidity and mortality. Algorithms incorporating multiple diagnostic and procedure codes…
  • Abstract Number: 0562 • ACR Convergence 2021

    Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018

    Patompong Ungprasert1, Thanat Chaikijurajai2, Karn Wijarnpreecha3 and Paul Kroner3, 1Cleveland Clinic, Cleveland Heights, OH, 2Cleveland Clinic, Cleveland, OH, 3Mayo Clinic Florida, Jacksonville, FL

    Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology